ProLynx, LLC
- Biotech or pharma, therapeutic R&D
Prolynx has developed a versatile technology platform for the half-life extension of a variety of drug modalties, ranging from peptides to small molecules and full-length proteins. Notably, half-lives of over a month can be achieved allowing injection intervals of one or more month. Prolynx's technology is based on the reversable conjugation of drugs to hydrogel microspheres that offer tunable release kinetics followed by subsequent gel degradation for the subcutaneous delivery. If a soluble, blood-circulating depot is preferred, Prolynx can also leverage it's tunable release platform for conjugation to soluble polymers.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}